Novartis acquires Kate Therapeutics to advance gene therapies
The deal includes an upfront payment in cash with added payments contingent on the achievement of certain milestones.
Cell & Gene Therapy
FDA shares additional draft guidance on CGTs
Lyell goes all in on CAR-T therapies, buys ImmPACT Bio and trims pipeline
Resolution scores $83m to develop macrophage cell therapies
Genespire raises $52m in Series B to trial paediatric gene therapy
The most expensive drugs in the US
Gene therapy: How Veristat cut trial database costs by 30%
APAC leaps ahead in adoptive cell therapy space
